Structural and functional insights into human Tudor-SN, a key component linking RNA interference and editing

Chia-Lung Li¹, Wei-Zen Yang¹, Yi-Ping Chen¹ and Hanna S. Yuan¹,²,*

¹Institute of Molecular Biology, Academia Sinica and ²Graduate Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC

Received January 29, 2008; Revised April 7, 2008; Accepted April 15, 2008

ABSTRACT

Human Tudor-SN is involved in the degradation of hyper-edited inosine-containing microRNA precursors, thus linking the pathways of RNA interference and editing. Tudor-SN contains four tandem repeats of staphylococcal nuclease-like domains (SN1–SN4) followed by a tudor and C-terminal SN domain (SN5). Here, we showed that Tudor-SN requires tandem repeats of SN domains for its RNA binding and cleavage activity. The crystal structure of a 64-kD truncated form of human Tudor-SN further shows that the four domains, SN3, SN4, tudor and SN5, assemble into a crescent-shaped structure. A concave basic surface formed jointly by SN3 and SN4 domains is likely involved in RNA binding, where citrate ions are bound at the putative RNase active sites. Additional modeling studies provide a structural basis for Tudor-SN’s preference in cleaving RNA containing multiple I/C1U wobble-paired sequences. Collectively, these results suggest that tandem repeats of SN domains in Tudor-SN function as a clamp to capture RNA substrates.

INTRODUCTION

Posttranscriptional regulation, such as RNA interference, editing and decay, plays important roles in many cellular processes, including viral defense, chromatin remodeling, genome rearrangement and gene expression. A number of RNases are critically involved in these processes, such as the RNase III enzymes Dicer and Drosha, which digest primary double-stranded RNA transcripts to produce siRNA and miRNA in RNA silencing (1,2). Recently, a novel miRNase (ribonuclease for small interference micro RNA), Tudor-staphylococcal nuclease-like (SN), has been shown to be involved in the degradation of hyper-edited miRNA primary transcripts and intriguingly links the pathways between RNA editing and RNA interference (3).

Tudor-SN, also called p100 or SND1, has been identified in mammals, fishes, Drosophila, Caenorhabditis elegans, ciliates (tetrahymena) and fission yeast (4–8). It is a ubiquitous protein with similar mRNA levels in human pancreas, muscle, liver, lung, placenta, brain and heart (9). Tudor-SN was first characterized as a transcription coactivator, interacting with several specific transcription factors to activate their activities, including EBNA-2 (9), c-Myb (10), STAT6 (11–13) and STAT5 (14). Some of these transcription factors regulate important cellular signaling pathways. For example, c-Myb is involved in hematopoietic cell growth, differentiation and apoptosis, while STAT6 is a critical interleukin-4-induced transcription factor in immune and anti-inflammatory responses. Tudor-SN was found to bridge between these specific transcription factors and component proteins of transcriptional machinery, for example, between c-Myb and Pim-1 (10), STAT6 and CBP (11), STAT6 and RNA HelicaseA (12) and STAT6 and PC1 (13). Activation of some of these transcription factors by Tudor-SN leads to cell proliferation and is linked to human diseases. For instance, Tudor-SN interacting with STAT6 and PC1 activates renal epithelial cell proliferation in autosomal-dominant polycystic kidney disease (ADPKD) (13). Up-regulation of Tudor-SN mRNA has also been observed in human colon cancer tissues and cell lines; however, in this case, posttranscriptional regulation of APC gene by Tudor-SN was suggested (15).

The involvement of Tudor-SN in posttranscriptional regulation was first hinted by the discovery that Tudor-SN is a component protein associated in RISC (RNA-induced silencing complex) (7). Human Tudor-SN was then shown to promote the cleavage of hyper-edited double-stranded RNA containing multiple I/U and U/I pairs (16,17). Subsequently, Tudor-SN was identified as a ribonuclease specific for inosine-containing primary transcripts of miRNA; it modulates miRNA processing and expression through RNA editing by ADAR (adenosine deaminase acting on RNA) (3,18). The primary transcript of human miRNA-142 is edited by ADAR enzymes, resulting in
suppression of its processing by Drosha, and the edited transcripts are further degraded by Tudor-SN. These results demonstrate that Tudor-SN plays an important role in the regulation of the biogenesis and expression of some miRNAs. Moreover, Tudor-SN interacts with U5 snRNP (small nuclear ribonucleoproteins) and functions in spliceosome assembly and pre-mRNA splicing (19). Therefore, this interesting protein appears to play multiple roles in transcriptional regulation, RNA interference, RNA editing and RNA splicing.

Sequence analyses have shown that Tudor-SN contains four tandem repeats of SN domains (SN1 to SN4) followed by a tudor and C-terminal partial SN domain (SN5, see domain organization in Figure 1A) (20,21). The SN domains share ~20% sequence identity with staphylococcal nuclease, which is a Ca\(^{2+}\)-dependent extracellular nuclease produced by Staphylococcus aureus (22). The tudor domain, bearing a barrel-like fold, is a protein–protein interaction domain, usually interacting with methylated peptides, such as the ones identified in SNM (23), 53BP1 (24), SPF30 and TDRD (25). The crystal structure of a C-terminal fragment of Tudor-SN (residues 654–870) containing the tudor domain and the C-terminal SN domain (SN5) shows that a conserved aromatic cage in the tudor domain may bind the methylated peptides of its interaction partners in snRNPs (26). However, it remains uncertain how Tudor-SN binds RNA and participates in RNA interference, editing and degradation. Here, we address the role of Tudor-SN in RNA binding and cleavage by biochemical and X-ray crystal structure analysis. Our results demonstrate that Tudor-SN adopts an interesting means, using its tandem repeats of SN domains, to capture RNA substrates.

MATERIALS AND METHODS

Cloning, expression and protein purification

The full-length cDNA of human Tudor-SN (residues 1–885) was purchased from the Open Biosystems (Huntsville, AL, USA) (Clone ID: 3345037). The DNA fragments of TSN (residues 22–863), TSN-90 (residues 114–885), TSN-64 (residues 315–863), TSN-SN34 (residues 1–885) was purchased from the Open Biosystems (Huntsville, AL, USA) (Clone ID: 3345037). The DNA fragments of TSN (residues 22–863), TSN-90 (residues 114–885), TSN-64 (residues 315–863), TSN-SN34 (residues 1–885) was purchased from the Open Biosystems (Huntsville, AL, USA) (Clone ID: 3345037). The DNA fragments of TSN (residues 22–863), TSN-90 (residues 114–885), TSN-64 (residues 315–863), TSN-SN34 (residues 1–885) was purchased from the Open Biosystems (Huntsville, AL, USA) (Clone ID: 3345037).

CodonPlus(DE3)-RIPL cells (Stratagene, La Jolla, CA, USA) for the activity and filter-binding assays. Cells were grown in the LB medium containing appropriate antibiotics to a density of ~0.6 OD\(_{600}\) and induced using 1 mM IPTG for 20 h at 30°C. After the induction, the cells were harvested by centrifugation and resuspended in cold lysis buffer containing 20 mM Tris–HCl, pH 7.9, 500 mM NaCl, 5 mM imidazole, 10 mM β-mercaptoethanol and EDTA-free protease inhibitor cocktail (Roche, Mannheim, Germany). The cells were then lysed by microfluidizer and the debris was removed by centrifugation (13000 r.p.m., 30 min at 4°C). The cell extracts were then loaded onto the Ni-NTA affinity column (Qiagen Inc., Chatsworth, CA, USA) and washed extensively with wash buffer containing 20 mM Tris–HCl, pH 7.9, 500 mM NaCl, 40 mM imidazole and 10 mM β-mercaptoethanol. The purified proteins were eluted with wash buffer containing 250 mM imidazole. Peak fractions were pooled, diluted immediately into the buffer containing 50 mM HEPES pH 7.0, 10 mM EDTA, 10% glycerol and then loaded onto the HiTrap Heparin column (Amersham Pharmacia Biotech, Uppsala, Sweden) and eluted using the NaCl gradient. For the TSN-50 and TSN-25, diluted protein was loaded onto the HiTrap Q column (Pharmacia) and also eluted using the NaCl gradient. Peak fractions from Heparin (TSN, TSN-90, TSN-70, TSN-64, and TSN-SN34) or Q (TSN-50, TSN-25) were concentrated and further purified using the gel filtration chromatography column (Superdex 200, Pharmacia) in the buffer containing 50 mM HEPES, pH 7.0, 250 mM NaCl, 10 mM β-mercaptoethanol and 10% glycerol. The purified protein samples were concentrated to ~10 mg/ml and stored at −80°C.

For crystallization experiments, TSN-64 was further overexpressed in BL21(DE3) harboring chaperone plasmid pG-KJE8 (Takara Bio Inc., Shiga, Japan) or methionine auxotrophic host B834 (Novagen). The wild-type TSN-64 protein was expressed and purified as described above, expect the final gel filtration buffer was changed to 50 mM HEPES, pH 7.0, 150 mM NaCl and 10 mM β-mercaptoethanol. The selenomethionine-labeled protein Se-TSN-64 was expressed from B834 in the minimal medium described in a previous study (27). The purification procedures of Se-TSN-64 were the same as wild-type TSN-64.

Crystallization, structural determination and refinement

Different truncated forms of Tudor-SN were screened for the initial crystallization conditions by the high-throughput robotic Honeybee (960 trials) system. The TSN-64 crystals appeared in Hampton Research Screen Index21 in 2 months. After minor modification, TSN-64...
was crystallized to a suitable size in 3 weeks in a cold room in a solution containing 50 mM HEPES, pH 7.0, 150 mM NaCl, 10 mM β-mercaptoethanol, against a reservoir of 1.44 M tri-ammonium citrate pH 7.0 by the hanging-drop vapor diffusion method. Se-TSN-64 also crystallized under the same condition using the wild-type protein crystals as microseeds.

The Se-TSN-64 crystals were freshly soaked in the mother liquor containing 20% glycerol prior to the data collection at −150°C. Three multiwavelength anomalous diffraction (MAD) data sets were collected by a CCD detector at SPring-8 Taiwan beamline BL-12B2. Diffraction data were processed and scaled by HKL2000 (28). Eight selenium sites were located and the initial MAD phases of Se-TSN-64 were calculated by the CNS program (29). The Se-TSN-64 model, built by COOT (30), contained 537 residues (315–634 and 645–860) including a N-terminal vector encoded methionine (Met314 in the model). The electron density maps at a loop between residues 634–645 and at the C-terminal tail (residues 861–863) were ill defined. The final Se-TSN-64 model had an R-factor of 17.46% for 51 544 reflections and an R_free of 20.93% for 5780 reflections, in the resolution range of 50–1.9 Å.

Cleavage and filter-binding assays

The RNA oligonucleotides for RNase activity assays were purchased from Dharmacon (Lafayette, CO, USA) containing IIU1- or AAUA-sequence: 5'-AC UGGACAIUICUCGGAGG-3'/5'-CCUCGGAGUIUU UGUCCAGU-3' (or AAUA/UAUU in the center). The top strands of the double-stranded RNA were 5’-end labeled with [γ-32p]ATP by the T4 PNK (NEB, Beverly, MA, USA). The 1 pmole double-stranded RNA substrates were then incubated with different truncated forms of Tudor-SN in the reaction buffer containing 20 mM Tris–HCl, pH 8.0, 100 mM NaCl, 2 mM MgCl₂, 1 mM β-mercaptoethanol and 1% glycerol for 8 h at 20°C. After the incubation, 1 µl of Proteinase K (10 mg/ml) was added into the reaction mixture and incubated for 30 min at 37°C. An equal volume of 2× TBE–urea sample buffers (Bio-Rad, Richmond, CA, USA) were then added into the reaction mixtures and heated to 70°C for 2 min prior to 20% denaturing polyacrylamide gel electrophoresis. After the electrophoresis, the gels were exposed to the phosphor-imaging plate (Fujifilm) and analyzed by the imaging system FLA-5000 (Fujifilm).

For filter-binding assays, double-stranded RNA were 5’-end labeled with [γ-32p]ATP in both strands by T4 PNK. The labeled dsRNA (25 fmol) were then incubated with the serial dilution of protein samples in the binding buffer containing 20 mM HEPES, pH 7.0, 20 mM NaCl,

### Table 1. Data collection and refinement statistics

| Crystal | Se-TSN-64 |
|---------|-----------|
| Beamline | Spring-8 Taiwan beamline BL-12B2 |
| Wavelength (Å) | Peak 0.979389 | Inflection 0.979545 | Remote 0.964305 |
| Resolution (Å) | 1.85 | 1.9 | 1.9 |
| Space group | C2 | C2 | C2 |
| a = 97.17 | a = 97.54 | a = 97.41 |
| b = 91.78 | b = 92.03 | b = 91.93 |
| c = 87.82 | c = 88.17 | c = 88.04 |
| β = 91.27 | β = 91.25° | β = 91.26° |
| Total reflections | 322 497 | 152 909 | 172 942 |
| Unique reflections | 64 175 | 60 203 | 68 052 |
| Completeness (%) | 97.9 | 97.9 | 97.8 |
| I/σ(I) – overall | 20.3 | 14.9 | 15 |
| I/σ(I) – last shell | 4.6 | 2.8 | 3.4 |
| Phasing power (centrics/acentrics) | 1.04/0.92 | 1.04/0.92 |
| Figure of merit (centrics/acentrics) | 0.67/0.45 | 0.67/0.45 |

| Refinement | |
| Resolution (Å) | 50–1.9 |
| Reflections (working/test) | 51 544/5 780 |
| Rmean/Rfree | 17.46/20.93 |
| R. M. S. bond length (Å) | 0.0053 |
| R. M. S. angles (°) | 1.23 |
| Ramachandran plot (most favored/ additional allowed/generously allowed) | (90.2/9.4/0.4) |

| Number of atoms | Protein 4242 | Water 690 |
| Average B-factor (Å²) | Protein 24.08 | Water 37.48 |

Nucleic Acids Research, 2008, Vol. 36, No. 11 3581

Downloaded from https://academic.oup.com/nar/article-abstract/36/11/3579/2410290 by guest on 29 July 2018
10 mM EDTA, 5 mM β-mercaptoethanol and 10% glycerol for 30 min at 4°C. The reaction mixtures were then passed through the filter-binding assay apparatus (Bio-Dot SF microfiltration apparatus, Bio-Rad). After extensive washing, the protein–RNA complex-bound nitrocellulose membrane and free RNA bound nylon membrane were air dried and exposed to a phosphorimaging plate. The intensities of protein–RNA complex and free RNA were quantified by the program AlphaImager IS-2200 (Alpha Innotech, San Leandro, CA, USA). The binding percentages were calculated and normalized. The apparent Kd values were estimated by one-site binding curve fitting using GraphPad Prism 4. The atomic coordinates and structural factors of TSN-64 have been deposited in the Protein Data Bank with a PDB ID of 3BDL.

RESULTS

Tandem repeats of SN domains are required for RNA binding and cleavage activity

Tudor-SN has been reported to contain both DNase and RNase activities (7). Interestingly, an amino acid sequence comparison between SN domains of Tudor-SN and staphylococcal nuclease showed that most of the critical active site residues have been mutated (21). To find out which SN domains are involved in substrate binding and cleavage, a number of deletion mutants of Tudor-SN were constructed (Figure 1A). We found that the full-length Tudor-SN was unstable and degraded into three major stable fragments after purification. According to the N-terminal sequencing analysis results of these stable degraded fragments, three truncated forms of Tudor-SN, TSN-90 (residues 114–885), TSN-70 (residues 280–885) and TSN-50 (residues 476–885), were constructed. Based on the secondary structure predictions, three more constructs, TSN (residues 22–863), TSN-64 (residues 315–863) and TSN-25 (residues 645–863) were prepared, in which the flexible loops at both the N- and C-terminal ends were deleted. All of these His-tagged Tudor-SN truncated proteins were then overexpressed in Escherichia coli and purified to homogeneity by chromatographic methods, using a Ni-NTA affinity column, followed by a heparin and a size exclusion column. The purified proteins were analyzed by 10% SDS–PAGE (Figure 1B) and had >98% purity with minor degraded fragments that were confirmed by the Tudor-SN-specific antibody (data not shown).

To test if the recombinant Tudor-SN proteins contained DNase activity, plasmid-nicking assays were carried out. The intensity of each substrate and product gel band was quantified and the estimated substrate cleavage percentages were listed at the bottom of the gel (Figure 1C). TSN, TSN-90 and TSN-70 had detectable DNase activity (14% to 3%), whereas TSN-64, TSN-50 and TSN-25 had residual activity (1%). This result suggests that the N-terminal SN domains, including SN1, and SN2, are required for efficient DNase activity. To test the RNase activity, 20-bp double-stranded RNAs, containing four wobble-paired IIUI/UIUU or four Watson–Crick base-paired AAUA/UAUU, were used as substrates for RNA digestion experiments. We found that TSN and TSN-90 cleaved IIUI-dsRNA with the highest activities (5 and 15%), whereas TSN-70, TSN-64, TSN-50 and TSN-25 had no detectable dsRNase activity (Figure 1D). Moreover, TSN and TSN-90 cleaved IIUI-dsRNA more efficiently than AAUA-dsRNA,
demonstrating that Tudor-SN indeed prefers to cleave I-U-containing double-stranded RNA, consistent with previous studies (3,16).

To find out why some of the truncated mutants do not cleave RNA efficiently, the dissociation constants between Tudor-SN truncated proteins and RNAs were measured by nitrocellulose filter-binding assays (Figure 2A and B), in the absence of magnesium ions. The results summarized in Figure 2E show firstly that the full-length TSN (residues 22–863) binds to IIUI- and AAUA-dsRNA with similar $K_d$ values in the range of 10–20 nM. This result indicates that Tudor-SN does not bind site-specifically to the IIUI sequence, but it also binds well to Watson–Crick base-paired RNAs. Second, the truncated proteins containing four tandem SN (TSN), three tandem SN (TSN-90) and two tandem SN (TSN-70 and TSN-64) domains all bind RNA, with $K_d$ values ranging from 20 to 700 nM. Nevertheless, the two truncated mutants, TSN-50 and TSN-25, which did not contain tandem SN domains, cannot bind either IIUI- or AAUA-dsRNA. These results suggest that the N-terminal SN domains are responsible for RNA binding and the C-terminal tudor and SN5 domains are not involved in RNA binding. To further investigate whether the C-terminal tudor and SN5 domains are required for RNA binding, we expressed and purified a C-terminal truncated mutant TSN-SN34 bearing only SN3 and SN4 domains. TSN-SN34 bound to IIUI- and AAUA-dsRNA with apparent $K_d$ values in the range of 80–160 nM, comparable to those of TSN-64. This result confirmed that the C-terminal tudor and SN5 domains are dispensable in RNA binding, and a minimum of two tandem SN domains in Tudor-SN are required for efficient double-stranded RNA binding.

Crystal structure of TSN-64

The different truncated forms of Tudor-SN were screened for crystallization conditions, and the construct of TSN-64

Figure 2. Nitrocellulose filter-binding assays between truncated Tudor-SN mutants and RNA. (A) The binding assays show that TSN, TSN-90, TSN-70 and TSN-64 all bind the 20-bp IIUI-dsRNA with comparable affinity, whereas TSN-50 and TSN-25 cannot bind RNA. (B) The filter-binding assays between Tudor-SN proteins and the 20-bp AAUA-dsRNA show that the truncated proteins containing more tandem repeats of SN domains bind AAUA-dsRNA better. TSN-50 and TSN-25 did not bind AAUA-dsRNA. (C) SDS–PAGE analysis of purified TSN-SN34. (D) The filter binding assays between TSN-SN34 and RNA. (E) The summary of the apparent dissociation constants ($K_d$) between Tudor-SN proteins and 20-bp IIUI- and AAUA-dsRNAs.
(residues 315–863) yielded diffraction-quality crystals. The crystal structure of TSN-64 was determined by MAD at a resolution of 1.9 Å based on the anomalous scattering from a Se-Met-labeled TSN-64 crystal, using diffraction data collected at Taiwan beamline BL-12B2 at SPring-8, Japan. The final structural model contained one protein molecule (residues 315–634 and 645–860), four citrate ions and 690 water molecules in an asymmetric unit of the C2 monoclinic cell (see diffraction and refinement statistics in Table 1). A long loop between SN4 and SN5 domains (residues 635–644) was disordered without visible electron density.

The four domains, SN3, SN4, tudor and SN5 in TSN-64 are arranged in a distorted crescent shape. SN5 is not a partial but a complete SN domain, but a tudor domain is inserted in SN5 and packed between SN4 and SN5. The electrostatic potential, mapped onto the solvent-accessible surfaces of TSN-64, calculated by APBS (32). The color scale was set from −5 kT/e (red) to +5 kT/e (blue). The molecular surfaces of tudor and SN5 are more acidic, whereas those of SN3 and SN4 are more basic.

Comparison of SN domains to staphylococcal nuclease

The three SN domains, SN3, SN4, and SN5, all bear an OB-fold of staphylococcal nuclease, containing mainly a
five-stranded β-barrel packed against three α-helices (Figure 4) (33). Although the overall OB-fold structures are similar, minor differences are present in loop and flanking regions. Superimposition of respective SN domains with staphylococcal nuclease [PDB accession code:1EY0 (34)] shows that SN3 contains two extra long loops, marked by red dashed circles. SN4 contains an extra pair of β-strands and an α-helix, delineated by the blue circles. SN5, on the other hand, more closely resembles the overall structure of staphylococcal nuclease, without the presence of extra long loops or inserted secondary structural elements.

Interestingly, the structural-based sequence alignment suggests that SN1 domain is more similar to SN3 with a sequence identity of 28.1% (Figure 5A). Moreover, SN1 contains the sequences that may align with the two extra long loops in SN3. On the other hand, the sequence of SN2 is more similar to that of SN4 (26.9% identity), because only SN2 bears the inserted sequences that may align with the extra N-terminal α-helix in SN4 (from Thr486-Gly500, marked in boxes in Figure 5B). In the crystal structure of TSN-64, SN3 and SN4 jointly form a structural module with a basic surface ideal for nucleic acid binding. Taken together, these results suggest that SN1 and SN2 likely also form a similar structural module for nucleic acid substrate recognition. The sequence alignment of SN1-SN2 to SN3-SN4 is shown in Figure 5B.

Two citrate ions are located at the basic surface near the putative active sites in the SN3 and SN4 domains, respectively. Superimposition of SN3 and SN4 separately with the staphylococcal nuclease–pdTp complex [PDB accession code: 2ENB (35)] shows that a citrate ion bound in SN3 overlaps with pdTp, and a citrate ion bound in SN4 is located next to pdTp. This result suggests that the citrate ions bound in TSN-64 likely mimic the phosphate-binding sites of nucleic acid molecules. Several residues surrounding the citrate ions, such as Asp329, His344, Arg349, Arg352 and Arg413 in SN3, and Ser513, Cys535, Arg537, Glu554 and Asn581 in SN4 (Figure 4D and E) are candidates for catalytic residues involved in metal-ion binding, phosphate binding or phosphodiester bond hydrolysis. In contrast, the residues surrounding the corresponding putative active site in SN5 (Figure 4F) are mostly hydrophobic, such as Leu669, Ala772, Val778, Gln777, Gln780 and Cys812, consistent with the hypothesis that this domain may not participate in nucleic acid binding or hydrolysis.

**DISCUSSION**

**SN domains in RNA binding and cleavage**

Our deletion experiments in Tudor-SN show that a minimum of two tandem repeats of SN domains are required for sufficient RNA binding. The recombinant Tudor-SN proteins indeed prefer to cleave a 20-bp I-U-containing RNA over an A-U-containing RNA. The crystal structure
of TSN-64 further shows that SN3 and SN4 domains form a compact structural module and jointly generate a basic surface suitable for RNA recognition. The question is how these two SN domains work together to recognize a double-stranded RNA.

We noticed that the two SN domains in TSN-64 are related to each other by a pseudo 2-fold symmetry (Figure 6B). This 2-fold symmetry might be linked to the protein function of RNA recognition since the two sugar-phosphate backbones of a double-helical RNA are also related approximately by a 2-fold symmetry. Therefore, the structural module of SN3–SN4 seems ideal for the interactions with a double-stranded RNA. We thus built a complex model by superimposition of the dyad axis between SN3 and SN4 in TSN-64 to the dyad axis in a 16-bp RNA [PDB accession code: 1DI2 (36)]. In this way, one of the rotational axes of the RNA molecule in the complex was fixed by the superposition. Another rotational axis was further constrained by the shape of the cleft, which allows the RNA helix to pass through in only one direction. The final model, displayed in Figure 6A, has a double-stranded RNA snugly bound at the concave side of the crescent-shaped structure, with one strand of phosphate backbone interacting mainly with one SN domain. It is possible that the SN1 and SN2 domains assemble together with SN3 and SN4 to create another concave surface for RNA binding.

This model of Tudor-SN–RNA complex is consistent with our biochemical and structural data, except that the phosphate backbones are far away from the putative active sites in SN3 and SN4 domains (marked as stars in Figure 6B). Previous biochemical studies showed that Tudor-SN efficiently cleave only the dsRNAs containing multiple I/C1U and U/C1I wobble base pairs, but not the RNAs containing the isosteric G/C1U and U/C1G wobble base pairs or Watson–Crick A/C1U base pairs (3,16,17,37). It has been shown that the RNA containing tandem I/C1U pairs are significantly less stable than the ones containing G/C1U or A/C1U base-paired RNAs; the melting points of an 8-bp RNA containing two or three tandem I/C1U base pairs are >20°C lower than those of G/C1U or A/U base-paired RNAs (38). Therefore, the dsRNA containing multiple I/U pairs might have a specific structure that is less stable and deviates considerably from a classical A-form structure.
It is likely that the I-U-containing RNA bound at Tudor-SN has a distorted open conformation so that the RNA backbones are displaced from a well-annealed structure and thus are bound at the active sites (schematic diagram in Figure 6C). Only the hyper-edited double-stranded RNA may adopt this specific conformation and therefore only the RNA substrates containing multiple I-U and U-I pairs can be cleaved efficiently by Tudor-SN. This explains previous observations showing that the in vitro-edited pri-miRNA-142 can be degraded sensitively by Tudor-SN in proportion to the number of A-I modifications (3). Moreover, our hypothesis that two SN domains form a structural module for dsRNA binding is further supported by sequence data showing that Tudor-SN from various species contains even numbers of tandem repeats of SN domains, that is, either four for human, mouse, fish, drosophila, *C. elegans* and fission yeast or two for tetrahymena.

**Biological roles of Tudor-SN and its substrates**

Our biochemical and structural data support the previous finding that Tudor-SN functions as a miRNase (RNase for microRNA), which is more specific for I-U-containing double-stranded RNA. To date, the ADAR deaminase-edited primary transcript of miRNA-142 is the only identified natural substrate for Tudor-SN (3). Mature miRNA-142 expression levels increased substantially in ADAR1 null or ADAR2 null mice since Drosha processed only the unedited primary miRNA transcripts but not the hyper-edited ones. Tudor-SN plays an opposite role in that it degrades the hyper-edited miRNA more efficiently than the unedited ones. Over the decades, considerable lines of evidence have accumulated showing that miRNAs play key roles in the regulation of gene expression and affect mRNA degradation and translation (39). Therefore, besides functioning as a transcription coactivator and regulating gene expression at the transcriptional level, Tudor-SN may likely degrade negative regulators of hyper-edited miRNA and thus upregulate gene expression at the posttranscriptional level.

Apart from hyper-edited primary transcripts of miRNA, are there other RNA types that may be good candidate substrates for Tudor-SN? Firstly, bioinformatics screening for A-I RNA editing sites based on the comparison of cDNA or EST sequences with the corresponding genome sequences predicted that >85% of pre-mRNAs are edited, with the majority in introns (>90%) and UTRs containing Alu repeats or LINE repeats in human transcriptome (40–43). These A-I edited pre-mRNAs, containing inverted repeats that fold into double-stranded RNA, are candidate substrates for Tudor-SN, which in turn, may control gene expression of mRNAs bearing repeat sequences (44). Second, the cytoplasmic ADAR1 is induced by interferon (45), implying that this enzyme is involved in antiviral defense. Combined with the finding demonstrating that a number of viral RNAs are hyper-edited, Tudor-SN might target these hyper-edited viral RNAs and work together with ADAR1 to combat viral infections (17). Third, up- or down-regulation of a number of miRNA levels has been shown to play a role in antiviral defense during viral infection not only in plants and invertebrates (46), but also in mammals, through the interferon system (47). Therefore, it will be intriguing to find out whether Tudor-SN is involved in the regulation of these host miRNA levels. As there is no direct evidence for the role of Tudor-SN in the degradation of hyper-edited pre-mRNA, viral RNA or host miRNA, more studies are needed to further reveal Tudor-SN’s natural substrates.
How Tudor-SN’s RNase activity is regulated is another important issue that has not yet been addressed. Tudor-SN is an ubiquitous protein present in the nucleus (4,9), cytoplasm (5,16), or both (7). It has been shown that a recombinant Tudor-SN, supplemented with a limited amount of Xenopus laevis oocyte extract, cleaved a IIUI-containing dsRNA much more efficiently than the unsupplemented one (16), indicating that some other factors may be involved in promoting its RNase activity. The recombinant Tudor-SN purified from yeast enhanced the cleavage of IIUI-dsRNA (20-mer) but no RNase activity was detected when the RNA substrates were incubated with 5 μM Tudor-SN alone (37). In contrast, the recombinant flag tagged Tudor-SN from HeLa cell digested inosine hyper-edited miRNA efficiently (3). In this study, the recombinant Tudor-SNs were purified from E. coli, and they had weak DNase and RNase activities. It is likely that Tudor-SN needs other cofactors to enhance its nuclease activity, or Tudor-SN prefers to digest a longer native hyper-edited substrate. The tudor domain in Tudor-SN is known to be a protein–protein interaction domain and it could interact with other cofactors for the regulation of Tudor-SN’s activities. The SN5 domain, appearing not to be involved in nucleic acid interactions, may also be a good candidate for the screening of protein–protein interaction partners. Our structure analysis thus paves the way for future functional analyses of this versatile protein in RNA editing, interference and splicing.

ACKNOWLEDGEMENTS

This work was supported by research grants from Academia Sinica and the National Science Council, Taiwan, ROC. Portions of this research were carried out at the National Synchrotron Radiation Research Center (BL-13B1 and BL-13C1), a national user facility supported by the National Science Council of Taiwan, ROC. The Synchrotron Radiation Protein Crystallography Facility is supported by the National Research Program for Genomic Medicine. C.-L.L. is an Academia Sinica Postdoctoral Fellow, and H.S.Y. is an Academia Sinica Investigator Awardee. Funding to pay the Open Access publication charges for this article was provided by Academia Sinica.

Conflict of interest statement. None declared.

REFERENCES

1. Ding,S.-W. and Voinnet,O. (2007) Antiviral immunity directed by small RNAs. Cell, 130, 413–426.
2. Mello,C.C. and Conte,D.J. (2004) Revealing the world of RNA interference. Nature, 431, 338–342.
3. Yang,W., Chendrimada,T.P., Wang,Q., Higuchi,M., Myers,M.M., Hannon,G.J. and Plasterk,R.H. (2003) A micrococcal nuclease homologue in RNAi effector complexes. Nature, 425, 411–414.
4. Howard-Till,R.A. and Yao,M.-C. (2007) Tudor nuclease genes and programmed DNA rearrangements in Tetranychus thermophila. Eukaryot. Cell, 6, 1795–1804.
5. Tong,X., Drapkin,R., Yalamanchili,R., Mosialos,G. and Kieff,E. (1995) The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIIE. Mol. Cell. Biol., 15, 4735–4744.
6. Leversen,J., Koskinen,P.J., Orrico,F., Rainio,E.-M., Jalkanen,K.J., Dash,A.B., Eisenman,R.N. and Hess,S.A. (1998) Pin-1 kinase and p100 cooperate to enhance c-Myb activity. Mol. Cell, 2, 417–425.
7. Valineva,T., Yang,J., Palovuori,R. and Silvennoinen,O. (2005) The transcriptional co-activator protein p100 recruits histone acetyltransferase activity to STAT6 and mediates interaction between the CREB-binding protein and STAT6. J. Biol. Chem., 280, 14989–14996.
8. Valineva,T., Yang,J. and Silvennoinen,O. (2006) Characterization of RNA helicase A as component of STAT6-dependent enhancement. Nucleic Acid Res., 34, 3938–3946.
9. Low,S.H., Vasanth,S., Larson,C.H., Mukherjee,S., Sharma,N., Kinter,M.T., Kanc,M.E., Obura,T. and Weinb,T. (2006) Polycystin-1, STAT6, and p100 function in a pathway that transduces ciliary mechanosensation and it activated in polycystic kidney disease. Develop. Cell, 10, 57–69.
10. Paukku,K., Yang,J. and Silvennoinen,O. (2007) Tudor and nuclease-like domains containing protein p100 function as coactivators for signal transducer and activator of transcriptional 5. Mol. Endocrinol., 17, 1805–1814.
11. Tsuchiya,N., Ochiai,M., Nakashima,K., Ubagai,T., Sugimura,T. and Nakagama,H. (2007) SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis. Cancer Res., 67, 9568–9576.
12. Scadden,A.D. (2005) The RISC subunit Tudor-SN binds to hyper-edited double-stranded RNA and promotes its cleavage. Nature Struct. Mol. Biol., 12, 489–496.
13. Scadden,A.D. and Smith,C.W.J. (2001) Specific cleavage of hyper-edited dsRNAs. EMBO J., 20, 4243–4252.
14. Kawahara,Y., Zinshteyn,B., Chendrimada,T.P., Shiekhattar,R. and Nishikura,K. (2007) RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer–TRBP complex. EMBO Rep., 8, 763–769.
15. Yang,J., Valineva,T., Hong,J., Bu,T., Yao,Z., Jensen,O.N., Frilander,M.J. and Silvennoinen,O. (2007) Transcriptional co-activator protein p100 interacts with snRNPs and facilitates the assembly of the spliceosome. Nucleic Acid Res., 35, 4485–4494.
16. Callebaut,I. and Morrow,J.P. (1997) The human EBNA-2 coactivator protein p100: multidomain organization and relationship to the staphylococcal nuclease fold and the tudor protein involved in DNA repair. J. Biol. Chem., 272, 14989–14996.
17. Ponting,C.P. (1997) P100, a transcriptional coactivator, is a human homologue of staphylococcal nuclease. Protein Sci., 6, 459–463.
18. Cotton,F.A., Hazen,E.E.J. and Legg,M.J. (1979) Staphylococcal nuclease: proposed mechanism of action based on structure of enzyme-thymidine 3’-5’-bisphosphate-calcium ion complex at 1.5-Angstrom resolution. Proc. Natl Acad. Sci. USA, 76, 2551–2555.
19. Selenko,P., Sprangers,R., Stier,G., Fisher,U. and Sattler,M. (2001) SMN tudor domain structure and its interaction with the Sm proteins. Nat. Struct. Biol., 8, 27–31.
20. Huyen,Y., Zgheib,O., DiTullio,R.A.J., Gorgoulis,V.G., Zacharatos,P., Petty,T.J., Sheston,E.A., Mellert,H.S., Stavridis,E. and Halazonetis,T.D. (2004) Methylylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature, 432, 406–411.
25. Cote, J. and Richard, S. (2005) Tudor domains bind symmetrical dimethylated arginines. *J. Biol. Chem.*, 280, 28476–28483.

26. Shaw, N., Zhao, M., Cheng, C., Xu, H., Saarikettu, J., Li, Y., Da, Y., Yao, Z., Silvennoinen, O., Yang, J. et al. (2007) The multifunctional human p100 protein 'hooks' methylated ligands. *Nat. Struct. Mol. Biol.*, 14, 779–784.

27. Li, C.L., Hor, L.I., Chang, Z.F., Tsai, L.C., Yang, W.Z. and Yuan, H.S. (2003) DNA binding and cleavage by the periplasmic nuclease Vvn: a novel structure with a known active site. *EMBO J.*, 22, 4014–4025.

28. Otwinowski, Z. and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol.*, 276, 307–326.

29. Brurter, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S. et al. (1998) Crystallography & NMR system: a new software suite for macromolecular structure determination. *Acta Crystallogr. D Biol. Crystallogr.*, 54, 905–921.

30. Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr. D.*, 60, 2126–2132.

31. Delano, W.L. (2002) *The PyMOL Molecular Graphics System*. Delano Scientific, Palo Alto, CA.

32. Baker, N.A., Sept, D., Joseph, S., Holst, M.J. and McCammon, J.A. (2001) Electrostatics of nanosystems: application to microtubules and the ribosome. *Proc. Natl Acad. Sci. USA*, 98, 10037–10041.

33. Theobald, D.T., Mitton-Fry, R.M. and Wuttke, D.S. (2003) Nucleic acid recognition by OB-fold proteins. *Annu. Rev. Biophys. Biomol. Struct.*, 32, 115–133.

34. Chen, J., Lu, Z., Sakon, J. and Sites, W.E. (2000) Increasing the thermostability of staphylococcal nuclease: implications for the origin of protein thermostability. *J. Mol. Biol.*, 303, 125–130.

35. Libson, A.M., Gittis, A.G. and Lattman, E.E. (1994) Crystal structures of the binary Ca2+ and pdTp complexes and the ternary complex of the Asp21->Glu mutant of staphylococcal nuclease. Implications for catalysis and ligand binding. *Biochemistry*, 33, 8007–8016.

36. Rytter, J.M. and Schultz, S.C. (1998) Molecular basis of double-stranded RNA-protein interactions: structure of a dsRNA-binding domain complexed with dsRNA. *EMBO J.*, 17, 7505–7513.

37. Scadden, A.D.J. and O’Connell, M.A. (2005) Cleavage of dsRNAs hyper-edited by ADARs occurs at preferred editing sites. *Nucleic Acid Res.*, 33, 5954–5964.

38. Serra, M.J., Smolter, P.E. and Westhof, E. (2004) Pronounced instability of tandem IU base pairs in RNA. *Nucleic Acid Res.*, 32, 1824–1828.

39. Valencia-Sanchez, M.A., Liu, J., Hannon, G.J. and Parker, R. (2007) Control of translation and mRNA degradation by miRNAs and siRNAs. *Genes Dev.*, 20, 515–524.

40. Athanasiadis, A., Rich, A. and Maas, S. (2004) Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. *PLoS Biol.*, 2, e391.

41. Blow, M., Futreal, P.A., Wooster, R. and Stratton, M.R. (2004) A survey of RNA editing in human brain. *Genome Res.*, 14, 2379–2387.

42. Kim, D.D., Kim, T.T., Walsh, T., Kobayashi, Y., Matise, T.C., Buyske, S. and Gabriel, A. (2004) Widespread RNA editing of embedded alu elements in the human transcriptome. *Genome Res.*, 14, 1719–1725.

43. Levanon, E.Y., Eisenberg, E., Yelin, R., Nemzer, S., Hallegger, M., Shemesh, R., Fligelman, Z.Y., Shoshan, A., Pollock, S.R., Sztybel, D. et al. (2004) Systematic identification of abundant A-to-I editing sites in the human transcriptome. *Nat. Biotechnol.*, 22, 1001–1005.

44. Nishikura, K. (2006) Editor meets silencer: crosstalk between RNA editing and RNA interference. *Nat. Rev. Mol. Cell. Biol.*, 7, 919–931.

45. Patterson, J.B. and Samuel, C.E. (1995) Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. *Mol. Cell. Biol.*, 15, 5376–5388.

46. Cullen, B.R. (2006) Is RNA interference involved in intrinsic antiviral immunity in mammals? *Nat. Immunol.*, 7, 563–567.

47. Pedersen, I.M., Cheng, G., Wieland, S., Volinia, S., Croce, C.M., Chisari, F.V. and David, M. (2007) Interferon modulation of cellular microRNAs as an antiviral mechanism. *Nature*, 449, 919–923.